Bicara Therapeutics (BCAX) Q1 2026 Earnings
BCAX·Reported May 11, 2026·Before market open
Diluted EPS came in at $-0.93 (-36.8% YoY), missed the $-0.64 consensus by $0.29.
Diluted EPS
$-0.93missed by $0.29
Consensus: $-0.64
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Bicara Therapeutics's Q1 2026 earnings report.
Bicara Therapeutics (BCAX) reported Q1 2026 earnings on May 11, 2026 before market open.
Bicara Therapeutics reported diluted EPS of $-0.93 for Q1 2026.
EPS missed the consensus estimate of $-0.64 by $0.29.
Compared to the same quarter a year prior, diluted EPS declined 36.8% from $-0.68.
You can read the 8-K earnings release (0001628280-26-033135) and the 10-Q periodic report (0001628280-26-033429) directly on SEC EDGAR. The filing index links above go to sec.gov.